NasdaqGS - Delayed Quote USD

Royalty Pharma plc (RPRX)

28.38 +0.29 (+1.03%)
At close: 4:00 PM EDT
28.38 0.00 (0.00%)
After hours: 6:13 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,238,561.00
2,354,554.00
2,237,215.00
2,289,463.00
2,122,353.00
Operating Expense
1,299,157.00
862,404.00
1,314,323.00
858,748.00
461,901.00
Operating Income
939,404.00
1,492,150.00
922,892.00
1,430,715.00
1,660,452.00
Net Non Operating Interest Income Expense
-121,463.00
-114,896.00
-109,626.00
-112,607.00
-128,680.00
Other Income Expense
368,785.00
322,834.00
-583,202.00
-76,907.00
170,182.00
Pretax Income
1,186,726.00
1,700,088.00
230,064.00
1,241,201.00
1,701,954.00
Net Income Common Stockholders
1,191,583.00
1,527,560.00
42,832.00
619,728.00
495,198.00
Diluted NI Available to Com Stockholders
1,191,583.00
1,527,560.00
42,832.00
619,728.00
495,198.00
Basic EPS
1.79
2.54
0.10
1.49
2.51
Diluted EPS
1.78
2.53
0.10
1.49
2.51
Basic Average Shares
448,353.75
447,601.00
437,963.00
414,794.00
388,135.00
Diluted Average Shares
600,457.00
602,900.00
437,972.00
414,802.00
388,135.00
Total Operating Income as Reported
939,404.00
1,492,150.00
307,065.00
1,430,715.00
1,595,399.00
Total Expenses
1,299,157.00
862,404.00
1,314,323.00
858,748.00
461,901.00
Net Income from Continuing & Discontinued Operation
798,857.00
1,134,834.00
42,832.00
619,728.00
975,040.00
Normalized Income
387,590.00
819,145.00
602,306.00
671,467.00
816,496.00
Interest Income
63,006.00
72,291.00
78,335.00
53,535.00
28,379.00
Interest Expense
184,469.00
187,187.00
187,961.00
166,142.00
157,059.00
Net Interest Income
-121,463.00
-114,896.00
-109,626.00
-112,607.00
-128,680.00
EBIT
1,371,195.00
1,887,275.00
418,025.00
1,407,343.00
1,859,013.00
EBITDA
1,371,195.00
1,887,275.00
423,695.00
1,430,339.00
1,882,071.00
Reconciled Depreciation
--
--
5,670.00
22,996.00
23,058.00
Net Income from Continuing Operation Net Minority Interest
798,857.00
1,134,834.00
42,832.00
619,728.00
975,040.00
Total Unusual Items Excluding Goodwill
411,267.00
315,689.00
-559,474.00
-51,739.00
158,544.00
Total Unusual Items
411,267.00
315,689.00
-559,474.00
-51,739.00
158,544.00
Normalized EBITDA
959,928.00
1,571,586.00
983,169.00
1,482,078.00
1,723,527.00
12/31/2020 - 6/16/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CYTK Cytokinetics, Incorporated
57.89
-6.78%
 
BBIO BridgeBio Pharma, Inc.
28.50
-2.06%
 
ARGX argenx SE
359.48
-4.04%
 
ROIV Roivant Sciences Ltd.
11.18
+0.45%
 
LEGN Legend Biotech Corporation
42.97
-0.62%
 
HALO Halozyme Therapeutics, Inc.
43.61
+1.07%
 
SPRO Spero Therapeutics, Inc.
1.6500
+0.61%
 
IONS Ionis Pharmaceuticals, Inc.
38.80
-0.72%
 
INCY Incyte Corporation
57.60
+8.56%
 
ASMB Assembly Biosciences, Inc.
13.39
-0.07%